TrialSignal
Clinical trial intelligence report
Phentermine/Topiramate as Preventive Pharmacotherapy for Obesity
Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.
Generated
Jun 17, 2026
NCT ID
NCT05834062
Status
WITHDRAWN
Phase
Phase 2
Sponsor
University of Minnesota
Executive brief
Investment-Ready Snapshot
The clinical trial, sponsored by the University of Minnesota, aims to evaluate the efficacy of phentermine/topiramate in preventing obesity in adolescents aged 16 to 22 with a BMI of 25-30 kg/m² and a family history of obesity. The trial has been withdrawn due to lack of funding, which raises concerns regarding the feasibility of further development. The obesity pharmacotherapy market is competitive, with established players and emerging therapies. The withdrawal of this trial may limit the potential for phentermine/topiramate as a preventive treatment in this demographic, impacting market positioning and investor confidence. Further diligence is required to assess alternative funding avenues or partnerships to revive the study.
Source & freshness
Provenance
https://clinicaltrials.gov/study/NCT05834062
Indication
Obesity, Adolescent
Modality
small molecule
Target
Phentermine and Topiramate act on the central nervous system to suppress appetite and enhance satiety, potentially influencing weight management through mechanisms related to neurotransmitter modulation.
Intervention
Qsymia and lifestyle management therapy, Placebo and lifestyle management therapy
Source record
Protocol Description
Detailed source ingestion pending.
Source record
Outcome Measures
Detailed source ingestion pending.
Source record
Eligibility
Detailed source ingestion pending.
AI analysis
Known Results And Readout Context
Detailed source ingestion pending.
IP intelligence
Patent And IP Landscape
Detailed source ingestion pending.
Source record
Contacts
Detailed source ingestion pending.